UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study

Annals of oncology, 2014-01, Vol.25 (1), p.160-165

2014

Volltextzugriff (PDF)

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer

Annals of oncology, 2009-11, Vol.20 (11), p.1794-1802

2009

Volltextzugriff (PDF)

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m(2) 24 h or 1.3 mg/m(2) 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer

Annals of oncology, 2009-11, Vol.20 (11), p.1794

2009

Volltextzugriff (PDF)

Adverse event profile by folate receptor status for vintafolide + pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer

Gynecologic oncology, 2014-06, Vol.133, p.178-178

2014

Volltextzugriff (PDF)

CA-125 as a response marker for vintafolide + pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer: The PRECEDENT trial

Gynecologic oncology, 2014-06, Vol.133, p.177-178

2014

Volltextzugriff (PDF)

European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer

International journal of gynecological cancer, 2017-05, Vol.27 (4), p.832-837

2017

Volltextzugriff (PDF)

8029 POSTER Health-Related Quality of Life (HRQoL)/Patient Reported Outcomes (PRO) of Patients (pts) With Partially Platinum Sensitive (PPS) Recurrent Ovarian Cancer (ROC) Treated in a Randomized Phase III Trial of Trabectedin and Pegylated Liposomal Doxorubicin (PLD) Vs PLD Alone (OVA-301) – an Exploratory Analysis

European journal of cancer (1990), 2011, Vol.47, p.S536-S536

2011

Volltextzugriff (PDF)

The value of tumor marker and cytokine analysis for the assessment of regional lymph node status in cervical cancer patients

International journal of gynecological cancer, 2008-11, Vol.18 (6), p.1279-1284

2008

Volltextzugriff (PDF)

8004 ORAL Safety and Efficacy Outcomes in Heavily and Non-heavily Pretreated Patients With Recurrent Ovarian Cancer (ROC) After Single-agent Trabectedin Treatment – Pooled Analysis of Phase II Trials

European journal of cancer (1990), 2011, Vol.47, p.S528-S529

2011

Volltextzugriff (PDF)

I043 THE ROLE OF SURGERY IN RELAPSED OVARIAN CANCER

International journal of gynecology and obstetrics, 2012-10, Vol.119 (S3), p.S171-S171

Bidziński, M.

2012

Volltextzugriff (PDF)

EP894 Evaluation of the clinical usefulness of HE4 and CA125 assays in monitoring treatment response of patients with advanced ovarian cancer

International journal of gynecological cancer, 2019-11, Vol.29 (Suppl 4), p.A483-A484

2019

Volltextzugriff (PDF)

EP386 Cervical cancer screening in PHC organization in poland

International journal of gynecological cancer, 2019-11, Vol.29 (Suppl 4), p.A259-A259

2019

Volltextzugriff (PDF)

44TiP ENGOT-ov65/KEYNOTE-B96: Phase III, randomized, double-blind study of pembrolizumab vs placebo + paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer

Annals of oncology, 2022-06, Vol.33, p.S400-S401

2022

Volltextzugriff (PDF)

Results of chemotherapy for pulmonary metastases of carcinoma of the cervix in patients after primary surgical and radiotherapeutic management

International journal of gynecological cancer, 2007-09, Vol.17 (5), p.1056-1061

2007

Volltextzugriff (PDF)

0173: Yolk Sac Tumor - Clinical Characteristic of Patients Group, Treatment, and Outcome

International journal of gynecological cancer, 2006-10, Vol.16 (Suppl 3), p.649-649

2006

Volltextzugriff (PDF)

0279: Evaluation of Prognostic Factors in Borderline Ovarian Tumors

International journal of gynecological cancer, 2006-10, Vol.16 (Suppl 3), p.680-680

2006

Volltextzugriff (PDF)

Comparison of the results of surgical treatment using laparoscopy and laparotomy in patients with endometrial cancer

International journal of gynecological cancer, 2005-09, Vol.15 (5), p.946-951

2005

Volltextzugriff (PDF)

The evaluation of intra‐ and postoperative complications related to debulking surgery with bowel resection in patients with FIGO stage III–IV ovarian cancer

International journal of gynecological cancer, 2007-09, Vol.17 (5), p.993-997

2007

Volltextzugriff (PDF)

0131: Primary Peritoneal Serous Papillary Carcinoma (PSPC)-Clinicopathologic Characteristics

International journal of gynecological cancer, 2006-10, Vol.16 (Suppl 3), p.638-638

2006

Volltextzugriff (PDF)

0491: Nadroparine Activated Fibrinolysis and Renal Function in Patient with Stage Iib-Iiib Cervical Cancer Treated with Radiochemotherapy

International journal of gynecological cancer, 2006-10, Vol.16 (Suppl 3), p.738-738

2006

Volltextzugriff (PDF)

39MO Phase III ENGOT-En9/LEAP-001 study: Lenvatinib + pembrolizumab (LEN/PEMBRO) vs chemotherapy (chemo) as first-line (1L) therapy for advanced or recurrent endometrial cancer

ESMO open, 2024-06, Vol.9, p.103539, Article 103539

2024

Volltextzugriff (PDF)

000432 COMPARISON OF PRETREATMENT MRI AND PROTON MR SPECTROSCOPY WITH SURGICO-PATHOLOGIC FINDINGS IN PATIENTS TREATED FOR STAGE I AND II INVASIVE CARCINOMA OF THE CERVIX

International journal of gynecological cancer, 2005-09, Vol.15 (Suppl 2), p.171-171

2005

Volltextzugriff (PDF)

0239: Prognostic Value of Pretreatment Serum Ca 125 and Cytokine Levels in Patients with Ovarian Cancer

International journal of gynecological cancer, 2006-10, Vol.16 (Suppl 3), p.668-668

2006

Volltextzugriff (PDF)

0512: Clinical Utility of Examining Tumor Markers and Cytokines in Patients with Cervical Adeno- Carcinoma

International journal of gynecological cancer, 2006-10, Vol.16 (Suppl 3), p.744-744

2006

Volltextzugriff (PDF)

894PPRECEDENT SUBSET ANALYSIS: SAFETY AND DISEASE CONTROL WITH VINTAFOLIDE MONOTHERAPY FOLLOWING DISCONTINUATION OF PEGYLATED LIPOSOMAL DOXORUBICIN (PLD)

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv312-iv312

2014

Volltextzugriff (PDF)

1 – 25 von 224

Suche als RSS-Feed

Aktive Filter

SpracheFranzösisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(197)
Mit Volltextzugriff
(154)

Publikationsform

Artikel
(223)
Tagungsberichte
(1)

Sprache

Englisch
(198)
Polnisch
(27)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(89)
Life Sciences & Biomedicine
(87)
Male
(79)
Humans
(70)
Animals
(62)
Female
(60)
Rats
(58)
Adult
(49)
Middle Aged
(44)
Biological And Medical Sciences
(42)
Neurosciences & Neurology
(34)
Pharmacology & Pharmacy
(32)
Neurosciences
(31)
Rats, Wistar
(30)
Aged
(27)
Medical Sciences
(25)
Behavioral Sciences
(23)
Ovarian Cancer
(21)
Oncology
(20)
Fundamental And Applied Biological Sciences. Psychology
(18)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m(2) 24 h or 1.3 mg/m(2) 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer

Adverse event profile by folate receptor status for vintafolide + pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer

CA-125 as a response marker for vintafolide + pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer: The PRECEDENT trial

European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer

The value of tumor marker and cytokine analysis for the assessment of regional lymph node status in cervical cancer patients

8004 ORAL Safety and Efficacy Outcomes in Heavily and Non-heavily Pretreated Patients With Recurrent Ovarian Cancer (ROC) After Single-agent Trabectedin Treatment – Pooled Analysis of Phase II Trials

I043 THE ROLE OF SURGERY IN RELAPSED OVARIAN CANCER

EP894 Evaluation of the clinical usefulness of HE4 and CA125 assays in monitoring treatment response of patients with advanced ovarian cancer

EP386 Cervical cancer screening in PHC organization in poland

44TiP ENGOT-ov65/KEYNOTE-B96: Phase III, randomized, double-blind study of pembrolizumab vs placebo + paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer

Results of chemotherapy for pulmonary metastases of carcinoma of the cervix in patients after primary surgical and radiotherapeutic management

0173: Yolk Sac Tumor - Clinical Characteristic of Patients Group, Treatment, and Outcome

0279: Evaluation of Prognostic Factors in Borderline Ovarian Tumors

Comparison of the results of surgical treatment using laparoscopy and laparotomy in patients with endometrial cancer

The evaluation of intra‐ and postoperative complications related to debulking surgery with bowel resection in patients with FIGO stage III–IV ovarian cancer

0131: Primary Peritoneal Serous Papillary Carcinoma (PSPC)-Clinicopathologic Characteristics

0491: Nadroparine Activated Fibrinolysis and Renal Function in Patient with Stage Iib-Iiib Cervical Cancer Treated with Radiochemotherapy

39MO Phase III ENGOT-En9/LEAP-001 study: Lenvatinib + pembrolizumab (LEN/PEMBRO) vs chemotherapy (chemo) as first-line (1L) therapy for advanced or recurrent endometrial cancer

000432 COMPARISON OF PRETREATMENT MRI AND PROTON MR SPECTROSCOPY WITH SURGICO-PATHOLOGIC FINDINGS IN PATIENTS TREATED FOR STAGE I AND II INVASIVE CARCINOMA OF THE CERVIX

0239: Prognostic Value of Pretreatment Serum Ca 125 and Cytokine Levels in Patients with Ovarian Cancer

0512: Clinical Utility of Examining Tumor Markers and Cytokines in Patients with Cervical Adeno- Carcinoma

894PPRECEDENT SUBSET ANALYSIS: SAFETY AND DISEASE CONTROL WITH VINTAFOLIDE MONOTHERAPY FOLLOWING DISCONTINUATION OF PEGYLATED LIPOSOMAL DOXORUBICIN (PLD)

Aktive Filter

Suchergebnisse filtern